195 related articles for article (PubMed ID: 21805124)
21. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket.
Gu SX; Xiao T; Zhu YY; Liu GY; Chen FE
Eur J Med Chem; 2019 Jul; 174():277-291. PubMed ID: 31051402
[TBL] [Abstract][Full Text] [Related]
23. Chemical structure and correlation analysis of HIV-1 NNRT and NRT inhibitors and database-curated, published inhibition constants with chemical structure in diverse datasets.
Viira B; García-Sosa AT; Maran U
J Mol Graph Model; 2017 Sep; 76():205-223. PubMed ID: 28738270
[TBL] [Abstract][Full Text] [Related]
24. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
Liu J; He X; Zhang JZ
J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
[TBL] [Abstract][Full Text] [Related]
25. Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
Bollini M; Gallardo-Macias R; Spasov KA; Tirado-Rives J; Anderson KS; Jorgensen WL
Bioorg Med Chem Lett; 2013 Feb; 23(4):1110-3. PubMed ID: 23298809
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation and molecular modeling studies of new 2,3-diheteroaryl thiazolidin-4-ones as NNRTIs.
Debnath U; Verma S; Singh P; Rawat K; Gupta SK; Tripathi RK; Siddiqui HH; Katti SB; Prabhakar YS
Chem Biol Drug Des; 2015 Nov; 86(5):1285-91. PubMed ID: 26031778
[TBL] [Abstract][Full Text] [Related]
27. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
28. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
Liu G; Wang W; Wan Y; Ju X; Gu S
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
[TBL] [Abstract][Full Text] [Related]
29. What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
Paneth A; Płonka W; Paneth P
J Mol Model; 2017 Oct; 23(11):317. PubMed ID: 29046967
[TBL] [Abstract][Full Text] [Related]
30. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in the Design and Development of Non-nucleoside Reverse Transcriptase Inhibitor Scaffolds.
Shirvani P; Fassihi A; Saghaie L
ChemMedChem; 2019 Jan; 14(1):52-77. PubMed ID: 30417561
[TBL] [Abstract][Full Text] [Related]
32. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
33. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
[TBL] [Abstract][Full Text] [Related]
36. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
37. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
38. Computer-aided discovery of anti-HIV agents.
Jorgensen WL
Bioorg Med Chem; 2016 Oct; 24(20):4768-4778. PubMed ID: 27485603
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
40. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
